There may be a reason Pfizer chose that curious tagline in the drugmaker's once-inescapable commercials for its COVID-19 oral antiviral – the subject of a "Saturday Night Live" parody – which cost U.S. taxpayers at least $12 billion before the feds tightened the spigot last fall and Pfizer jacked the price to $1,390 for a five-day course.
The nirmatrelvir-ritonavir combination marketed as Paxlovid does no better against so-called long COVID than a placebo taken with ritonavir, according to a new "original investigation" quietly released Friday in JAMA Internal Medicine, published by the Journal of the American Medical Association.
The post Feds Bet on Wrong COVID Horse Again as Pfizer’s Own Research Casts Doubt on Pricey Paxlovid appeared first on The Connecticut Star.